Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss

Completed · Phase 1

Conditions studied: Sensorineural Hearing Loss

In brief

To determine if autologous human umbilical cord blood infusion in children with acquired hearing loss is safe, feasible, improves inner ear function, audition and language development.

Key facts

Study ID

NCT02038972

Run by

James Baumgartner, MD

People needed

11

Starts

2013-01-01

Expected to finish

2017-01-10

Last updated by the study team

2026-07-09

Who can join

Age: 0 and older, up to 6. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Evidence of a sensorineural hearing loss
• Unilateral or bilateral in configuration
• Symmetrical or asymmetrical configuration
• Sudden or progressive in presentation
• Moderate to profound in degree (40-90 Decibels (dB) in at least one ear
• Normally shaped cochlea, as determined by MRI
• The loss must be considered:
• Acquired
• Unknown with a negative genetic test.
• Fitted for hearing aids no later than six months post detection of loss.
• Enrollment in a parent/child intervention program
• Age 6 weeks - 6 years old at time of infusion with less than 18 months of hearing loss at the time of cord blood infusion.
• Ability of the child and caregiver to travel to Orlando, and stay for at least 4 days, and to return for all follow-up visits.

You may not qualify if…

• Inability to obtain all pertinent medical records:
• (pertinent physician notes, speech language pathology notes, laboratory findings, test results and imaging studies-must be sent to the research team at least prior to the subject arriving at the study location for preliminary screening and eligibility assessment, preferably14 days before the scheduled hUBC treatment.)
• Known history of:
• Recently treated infection less than 2 weeks before infusion.
• Renal disease of altered renal function as defined by serum creatinine > 1.5 mg/dl at admission.
• Hepatic disease or altered liver function as defined by SGPT > 150 U/L, and or T. Bilirubin > 1.3 mg/dL
• Malignancy
• Immunosuppression as defined by WBC < 3,000 at admission
• Human Immunodeficiency Virus (HIV)
• Hepatitis B
• Hepatitis C
• Evidence of an extensive stroke (> 100ml lesion)
• Pneumonia, or chronic lung disease requiring oxygen
• Genetic syndromic sensorineural hearing loss
• hUBC sample contamination
• Banked cord cells totaling less than 6x106 mononuclear cells/kilogram body weight.
• Evidence of the following maternal infections during the pregnancy (Hepatitis A, Hepatitis B, Hepatitis C, HIV 1, HIV 2, Human T-lymphotropic Virus (HTLV) 1, HTLV 2 (CMV and Syphilis can be included in the study)
• participation in a concurrent intervention study
• Unwillingness or inability to stay for 4 days following hUBC infusion (should problems arise following the infusion) and to return for the one month, six month and one year follow-up visits.
• Presence of a cochlear implantation device
• Evidence of a genetic syndrome
• Evidence of conductive hearing loss
• Documented recurrent middle ear infections which are frequent (>5 per year)
• Otitis media at the time of examination
• Sensorineural loss is mild

Where it is running

• Florida Hospital — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.